Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
BACKGROUND: Our aim was to investigate the clinical efficacy and toxicity of metronomic administration of low-dose cyclophosphamide (Cy) in lymphoma and sarcoma rat tumour models. METHODS: Adult inbred rats were challenged with lymphoma TACB and sarcoma E100 s.c. on day 0. Animals were divided in...
Guardado en:
| Autores principales: | Rozados, Viviana R., Sánchez, Andrea M., Gervasoni, Silvia I., Berra, Héctor H., Matar, Pablo, Scharovsky, O. Graciela |
|---|---|
| Formato: | artículo publishedVersion article |
| Lenguaje: | Inglés |
| Publicado: |
Oxford University Press
2012
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/2133/2013 http://hdl.handle.net/2133/2013 |
| Aporte de: |
Ejemplares similares
-
The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
por: Rozados, Viviana R., et al.
Publicado: (2012) -
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018) -
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018) -
Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
por: Perroud, Herman A, et al.
Publicado: (2018) -
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018)